<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04924530</url>
  </required_header>
  <id_info>
    <org_study_id>19/NW/0630</org_study_id>
    <nct_id>NCT04924530</nct_id>
  </id_info>
  <brief_title>Lactose and Lipids</brief_title>
  <official_title>Revealing the Mechanisms by Which Milk Sugars Exaggerate Postprandial Lipaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bath</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>British Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Bath</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine to what extent ingestion of free sugars influence postprandial&#xD;
      triglyceridaemia in men and women.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each participant will undergo three experimental trials in a randomized, crossover research&#xD;
      design. On each study day, participants will consume a test drink containing standardised&#xD;
      amounts of carbohydrate and fat followed by collection of blood and breath samples to assess&#xD;
      metabolic responses during the 6 hour postprandial period. Trials will be identical except&#xD;
      for the type of carbohydrate contained within the test drink: 1) maltodextrin (glucose&#xD;
      polymer), 2) lactose (galactose-glucose disaccharide) and 3) sucrose (fructose-glucose&#xD;
      disaccharide).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 7, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postprandial changes in plasma triglyceride concentrations</measure>
    <time_frame>6 hours</time_frame>
    <description>Incremental area under the curve (iAUC) of plasma triglyceride concentrations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postprandial de novo lipogenesis (DNL)</measure>
    <time_frame>6 hours</time_frame>
    <description>Time course for synthesis of fatty acids from non-lipid precursors using stable isotope methodology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary fat oxidation</measure>
    <time_frame>6 hours</time_frame>
    <description>Time course for whole-body dietary fatty acid oxidation using stable isotope methodology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial changes in plasma insulin concentrations</measure>
    <time_frame>6 hours</time_frame>
    <description>Incremental area under the curve (iAUC) of plasma insulin concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial changes in plasma glucose concentrations</measure>
    <time_frame>6 hours</time_frame>
    <description>Incremental area under the curve (iAUC) of plasma glucose concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial changes in plasma galactose concentrations</measure>
    <time_frame>6 hours</time_frame>
    <description>Incremental area under the curve (iAUC) of plasma galactose concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial changes in plasma fructose concentrations</measure>
    <time_frame>6 hours</time_frame>
    <description>Incremental area under the curve (iAUC) of plasma fructose concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial changes in plasma VLDL-rich triglyceride [Svedberg flotation rate (Sf): 20-400] concentrations</measure>
    <time_frame>6 hours</time_frame>
    <description>Incremental area under the curve (iAUC) of plasma VLDL-rich triglyceride [Svedberg flotation rate (Sf): 20-400] concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial changes in plasma chylomicron-rich triglyceride (Sf: &gt;400) concentrations</measure>
    <time_frame>6 hours</time_frame>
    <description>Incremental area under the curve (iAUC) of plasma chylomicron-rich triglyceride (Sf: &gt;400) concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial changes in plasma lactate concentrations</measure>
    <time_frame>6 hours</time_frame>
    <description>Incremental area under the curve (iAUC) of plasma lactate concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial changes in plasma non-esterified fatty acid concentrations</measure>
    <time_frame>6 hours</time_frame>
    <description>Incremental area under the curve (iAUC) of plasma non-esterified fatty acid concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial changes in plasma beta-hydroxybutyrate concentrations</measure>
    <time_frame>6 hours</time_frame>
    <description>Incremental area under the curve (iAUC) of plasma beta-hydroxybutyrate concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial changes in plasma uric acid concentrations</measure>
    <time_frame>6 hours</time_frame>
    <description>Incremental area under the curve (iAUC) of plasma uric acid concentrations</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Cardiovascular Risk Factor</condition>
  <condition>Lipaemia</condition>
  <condition>Metabolic Disease</condition>
  <arm_group>
    <arm_group_label>Maltodextrin</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Glucose polymer; a common sugar substitute</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sucrose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fructose-glucose disaccharide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Galactose-glucose disaccharide</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Maltodextrin</intervention_name>
    <description>Co-ingestion of maltodextrin with a high fat meal</description>
    <arm_group_label>Maltodextrin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sucrose</intervention_name>
    <description>Co-ingestion of sucrose with a high fat meal</description>
    <arm_group_label>Sucrose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactose</intervention_name>
    <description>Co-ingestion of lactose with a high fat meal</description>
    <arm_group_label>Lactose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        â€¢ Age: 18-50 years and premenopausal (for women)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Weight instability (&gt;5 kg change in body mass within last 6 months)&#xD;
&#xD;
          -  Diagnosis of any form of diabetes&#xD;
&#xD;
          -  Intolerances or allergies to any of the study procedures (e.g. lactose intolerance)&#xD;
&#xD;
          -  Galactose disorders (e.g. galactokinase deficiency, UDPgalactose-4-epimerase&#xD;
             deficiency, galactose-1-phosphate uridyl transferase deficiency)&#xD;
&#xD;
          -  Fructose malabsorption&#xD;
&#xD;
          -  Inborn errors of fructose metabolism (e.g. fructokinase deficiency, aldolase B&#xD;
             deficiency, fructose-1,6-bisphosphatase deficiency)&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Any condition that could introduce bias to the study (e.g. diagnoses of lipid&#xD;
             disorders, including cardiovascular disease, or therapies that alter lipid or glucose&#xD;
             metabolism, such as statins or niacin).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department for Health, University of Bath</name>
      <address>
        <city>Bath</city>
        <state>Somerset</state>
        <zip>BA2 7AY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Carter, PhD</last_name>
      <phone>+44 (0) 1225 384654</phone>
      <email>sc2988@bath.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Javier T Gonzalez, PhD</last_name>
      <phone>+44 (0) 1225 385518</phone>
      <email>J.T.Gonzalez@bath.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Dylan Thompson, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Betts, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francoise Koumanov, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 7, 2021</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Bath</investigator_affiliation>
    <investigator_full_name>Steven Carter</investigator_full_name>
    <investigator_title>Research Associate</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Raw data will be made available online upon publication in a peer-reviewed journal.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

